Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported R&D Expense of $12.43 million for fiscal year 2025.
HERON THERAPEUTICS, INC. /DE/ R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $12.43M | -25.5% |
| 2024 | $16.68M | -57.4% |
| 2023 | $39.13M | -52.7% |
| 2022 | $82.70M | -36.8% |
| 2021 | $130.82M | -25.0% |
| 2020 | $174.53M | +4.3% |
| 2019 | $167.38M | +19.5% |
| 2018 | $140.03M | +1.0% |
| 2017 | $138.58M | +34.4% |
| 2016 | $103.12M | +68.6% |
| 2015 | $61.18M | +11.6% |
| 2014 | $54.83M | +68.6% |
| 2013 | $32.52M | +114.3% |
| 2012 | $15.17M | +84.9% |
| 2011 | $8.21M | +13.0% |
| 2010 | $7.26M | -6.8% |
| 2009 | $7.80M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.47M | -22.3% | +18.3% |
| June 30, 2025 | $2.93M | -33.8% | +28.7% |
| March 31, 2025 | $2.28M | -50.5% | -49.0% |
| September 30, 2024 | $4.46M | -51.9% | +0.7% |
| June 30, 2024 | $4.43M | -66.4% | -3.8% |
| March 31, 2024 | $4.61M | -47.8% | -50.4% |
| September 30, 2023 | $9.29M | -63.7% | -29.7% |
| June 30, 2023 | $13.21M | -54.2% | +49.5% |
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -25.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, HERON THERAPEUTICS, INC. /DE/’s r&d expense has grown by 59.4% (from $7.80 million to $12.43 million).
- The most recent figure is from HERON THERAPEUTICS, INC. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: